Puma Biotechnology Inc
Research Puma Biotechnology Inc (PBYI) on Bullrun: valuation model: 14.3% overvalued, market cap USD 525.85M, P/E 19.9. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPBYI
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal14.3% overvalued
- Market capUSD 525.85M
- P/E19.9
- Financial periodQ2 2026
- RevenueUSD 56.50M
- Net incomeUSD 8.19M
- Free cash flowUSD 1.62M
- Gross margin77.9%
Valuation Snapshot
Bullrun's latest valuation model marks Puma Biotechnology Inc as 14.3% overvalued; latest market cap is USD 525.85M; P/E is 19.9.
Peer valuation comparison
Latest P/E is 19.93x versus a Healthcare sector median of 24.6x (19.0% below).
Latest P/E is 19.93x versus a United States median of 23.85x (16.4% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 228.37M | USD 31.11M | USD 41.73M | 74.5% | 0.61 | USD 29.64M | USD 22.52M | USD 130.34M |
| FY2024 | USD 230.47M | USD 30.28M | USD 38.86M | 72.1% | 0.62 | USD 69.22M | USD 67.05M | USD 92.13M |
| FY2023 | USD 235.64M | USD 21.59M | USD 26.87M | 73.4% | 0.45 | USD 84.59M | USD 99.66M | USD 53.44M |
| FY2022 | USD 228.03M | USD 2.00K | -USD 15.83M | 75.8% | 0 | USD 76.20M | USD 98.31M | USD 21.61M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 525.85M | 19.9 | n/a | n/a |
| 2025 | 2025-12-31 | USD 299.93M | 9.8 | n/a | n/a |
| 2024 | 2024-12-31 | USD 149.77M | 5.0 | n/a | n/a |
| 2023 | 2023-12-29 | USD 205.98M | 61.9 | n/a | n/a |
| 2022 | 2022-12-30 | USD 196.04M | 19.2 | n/a | n/a |
| 2021 | 2021-12-31 | USD 125.17M | n/a | n/a | n/a |
About Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Puma Biotechnology Inc overvalued or undervalued?
Bullrun's valuation model currently marks Puma Biotechnology Inc as 14.3% overvalued.
What is Puma Biotechnology Inc's market cap?
Puma Biotechnology Inc's market capitalization is USD 525.85M.
What is Puma Biotechnology Inc's P/E ratio?
Puma Biotechnology Inc's price-to-earnings (P/E) ratio is 19.9.
What does Puma Biotechnology Inc do?
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.